149 related articles for article (PubMed ID: 11886463)
1. Clinical outcomes and resource utilization associated with haemophilia care in Europe.
Schramm W; Royal S; Kroner B; Berntorp E; Giangrande P; Ludlam C; Gringeri A; Berger K; Szucs T;
Haemophilia; 2002 Jan; 8(1):33-43. PubMed ID: 11886463
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.
Royal S; Schramm W; Berntorp E; Giangrande P; Gringeri A; Ludlam C; Kroner B; Szucs T;
Haemophilia; 2002 Jan; 8(1):44-50. PubMed ID: 11886464
[TBL] [Abstract][Full Text] [Related]
3. Real-world resource use and costs of haemophilia A-related bleeding.
Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
[TBL] [Abstract][Full Text] [Related]
4. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
Globe DR; Curtis RG; Koerper MA;
Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
6. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
Szucs TD; Offner A; Kroner B; Giangrande P; Berntorp E; Schramm W
Haemophilia; 1998 Jul; 4(4):498-501. PubMed ID: 9873781
[TBL] [Abstract][Full Text] [Related]
7. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
8. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
10. Outcome in moderate haemophilia.
den Uijl I; Biesma D; Grobbee D; Fischer K
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s330-6. PubMed ID: 23245711
[TBL] [Abstract][Full Text] [Related]
11. A comparison between prophylaxis and on demand treatment for severe haemophilia.
Khoriaty R; Taher A; Inati A; Lee C
Clin Lab Haematol; 2005 Oct; 27(5):320-3. PubMed ID: 16178913
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
Iannazzo S; Cortesi PA; Crea R; Steinitz K; Mantovani LG; Gringeri A
Blood Coagul Fibrinolysis; 2017 Sep; 28(6):425-430. PubMed ID: 27898515
[TBL] [Abstract][Full Text] [Related]
13. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.
Berger K; Schopohl D; Eheberg D; Auerswald G; Kurnik K; Schramm W
Klin Padiatr; 2013 May; 225(3):152-8. PubMed ID: 23519749
[TBL] [Abstract][Full Text] [Related]
14. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.
Oldenburg J; Zimmermann R; Katsarou O; Theodossiades G; Zanon E; Niemann B; Kellermann E; Lundin B;
Haemophilia; 2015 Mar; 21(2):171-179. PubMed ID: 25470205
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the benefits of prophylaxis in the management of hemophilia A.
Hoots WK; Nugent DJ
Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
[TBL] [Abstract][Full Text] [Related]
16. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
17. Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients.
Ingerslev J; Lethagen S; Hvitfeldt Poulsen L; Sørensen B; Lopatina E; Tentsova I; Yastrubinetskaya O; Plyushch OP
Haemophilia; 2014 Jan; 20(1):58-64. PubMed ID: 24354479
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis in adults with haemophilia.
Hay CR
Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
